Doxorubicin HCl Liposome (Doxorubicin HCl PEG-Liposomal) Patent Expiration, LOE Window & CMS Spending

Doxorubicin HCl Liposome (Doxorubicin HCl PEG-Liposomal) by Sun Pharmaceutical: Off-Patent Genericized (AB Competition), 0 AB generics, $2.5M 2024 CMS Part D & Medicaid spend, and $1,250 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSun Pharmaceutical
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.5M
2024 Medicare Part D Spend$427K
2024 Medicaid Spend$2.1M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,250 intro WAC)